Action ALRN AILERON THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Aileron Therapeutics, Inc.

Actions

ALRN

US00887A2042

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 06/05/2024 		Varia. 5j. Varia. 1 janv.
3,95 USD +5,05% Graphique intraday de Aileron Therapeutics, Inc. -19,72% +29,57%
03/05 Aileron Therapeutics clôture une offre directe d'actions et de bons de souscription MT
01/05 Transcript : Aileron Therapeutics, Inc. - Special Call

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Aileron Therapeutics Closes Direct Offering of Shares, Warrants
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Aileron Therapeutics : Corporate Presentation April 2024
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Aileron Therapeutics : Management Change/Compensation - Form 8-K
Aileron Therapeutics, Inc. Announces CFO Changes
Aileron Therapeutics, Inc. Announces Board Changes
Aileron Therapeutics Names Brian Windsor as CEO
Aileron Therapeutics Announces CEO Transition
Aileron Therapeutics, Inc. Announces Appointment of Brian Windsor as President and to the Board of Directors
Aileron Therapeutics, Inc. Announces CEO Changes
Aileron Therapeutics, Inc. Announces Resignation of Nolan Sigal, M.D., Ph.D. from Board of Directors, Member of Nominating and Corporate Governance Committee
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ALRN
  4. Actualités Aileron Therapeutics, Inc.
  5. Autres langues